As Terns shares soar 1,400%, what does a fund’s $5.2 million sale tell investors?
On February 17, 2026, Acorn Capital Advisors reported the sale of 225,000 shares of Terns Pharmaceuticals (NASDAQ:TERN)an estimated trade of $5.20 million based on the quarterly average price. According to a filing with the Securities and Exchange Commission on February 17, 2026, Acorn Capital Advisors reduced its position in Terns Pharmaceuticals (NASDAQ:TERN) for 225,000 shares…